Cargando…

GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data

Patients with type 2 diabetes (T2DM) have a substantial risk of developing cardiovascular disease. The strong connection between the severity of hyperglycaemia, metabolic changes secondary to T2DM and vascular damage increases the risk of macrovascular complications. There is a challenging demand fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sposito, Andrei C., Berwanger, Otávio, de Carvalho, Luiz Sérgio F., Saraiva, José Francisco Kerr
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292070/ https://www.ncbi.nlm.nih.gov/pubmed/30545359 http://dx.doi.org/10.1186/s12933-018-0800-2

Ejemplares similares

Correction to: GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
por: Sposito, Andrei C., et al.
Publicado: (2019)

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
por: Saraiva, Francisco Kerr, et al.
Publicado: (2014)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
por: Razavi, Michael, et al.
Publicado: (2022)

GLP-1RAs and cardiovascular disease: is the endothelium a relevant platform?
por: Menghini, Rossella, et al.
Publicado: (2023)

Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications
por: Heile, Michael, et al.
Publicado: (2018)

An overview of GLP-1 agonists and recent cardiovascular outcomes trials
por: Sheahan, Kelsey H, et al.
Publicado: (2020)

SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
por: Qiu, Mei, et al.
Publicado: (2021)

Commentary: SGLT2is vs. GLP1RAs reduce cardiovascular and all-cause mortality
por: Du, Lixin, et al.
Publicado: (2022)

Substantially different findings concerning the cardiovascular and cerebrovascular effectiveness of GLP1RAs vs. SGLT2is
por: Du, Lixin, et al.
Publicado: (2022)

Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients
por: Saraiva, José Francisco Kerr, et al.
Publicado: (2021)

GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes
por: del Olmo-Garcia, María Isabel, et al.
Publicado: (2018)

Compliance with Cardiovascular Prevention Guidelines in Type 2 Diabetes Individuals in a Middle-Income Region: A Cross-Sectional Analysis
por: Barreto, Joaquim, et al.
Publicado: (2022)

Effectiveness of SGLT2is vs. GLP-1RAs on cardiovascular and cerebrovascular outcomes in T2D patients according to CVD status
por: Du, Lixin, et al.
Publicado: (2022)

The Cardiovascular Effects of GLP-1 Receptor Agonists
por: Okerson, Theodore, et al.
Publicado: (2012)

Do Changes in Innate Immunity Underlie the Cardiovascular Benefits of Exercise?
por: Chuong, Phillip, et al.
Publicado: (2019)

Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies
por: Li, Junfeng, et al.
Publicado: (2017)

Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results: can definition of established cardiovascular disease be the missing link?
por: Melo, Miguel, et al.
Publicado: (2021)

Editorial: Beyond Cardiovascular Disease: Challenging New Pathways in Lipid and Lipoprotein Metabolism
por: Passarelli, Marisa, et al.
Publicado: (2022)

Primary Prevention of Cardiovascular Disease at Community Clinics in the State of Sao Paulo, Brazil: Results from the Epidemiological Information Study of Communities
por: Fonseca, Henrique Andrade R., et al.
Publicado: (2023)

Comparative cardiovascular effects of GLP‐1 agonists using real‐world data
por: Wallia, Amisha, et al.
Publicado: (2023)

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
por: Helmstädter, Johanna, et al.
Publicado: (2021)

Do arterial stiffness and wave reflection underlie cardiovascular risk in ethnic minorities?
por: Faconti, Luca, et al.
Publicado: (2016)

GLP-1RAs and SGLT2is Reduce Cardiovascular Events Independent of Reductions of Systolic Blood Pressure and Body Weight: A Meta-Analysis with Meta-Regression
por: Qiu, Mei, et al.
Publicado: (2020)

Cardiovascular Benefits of GLP-1 Receptor Agonism: Is Inflammation a Key?
por: Marx, Nikolaus, et al.
Publicado: (2018)

Cystatin C as a Candidate Biomarker of Cardiovascular Outcomes: Too Near, but too Far from Reality
por: de Carvalho, Luiz Sérgio F., et al.
Publicado: (2018)

Glucose-Lowering and the Risk of Cardiovascular Events With Antidiabetic Therapies: A Systematic Review and Additive-Effects Network Meta-Analysis
por: de Carvalho, Luiz Sergio Fernandes, et al.
Publicado: (2022)

Cardiovascular safety outcomes of once‐weekly GLP‐1 receptor agonists in people with type 2 diabetes
por: Goldman, Jennifer D.
Publicado: (2020)

Tuberculosis and Cardiovascular Complications: An Overview
por: Adefuye, Mayowa A, et al.
Publicado: (2022)

Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes
por: Zhang, Zeqing, et al.
Publicado: (2017)

AB006. Erectile dysfunction (ED) as a marker for cardiovascular diseases (CVD)
por: Torres, Luiz Otavio
Publicado: (2015)

DNA methylation changes underlie the long-term association between periodontitis and atherosclerotic cardiovascular disease
por: Omar, Mohamed, et al.
Publicado: (2023)

Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease
por: Toth, Peter P
Publicado: (2014)

Therapeutic Effects of Wenxin Keli in Cardiovascular Diseases: An Experimental and Mechanism Overview
por: Tian, Guihua, et al.
Publicado: (2018)

Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

FRI639 Effect Of Early Initiation Of GLP-1 RAs On Weight Reduction Among People With Type 2 Diabetes
por: Chinthammit, Chanadda, et al.
Publicado: (2023)

Circular RNAs in Cardiovascular Disease: An Overview
por: Fan, Ximin, et al.
Publicado: (2017)

Intermittent Fasting in Cardiovascular Disorders—An Overview
por: Malinowski, Bartosz, et al.
Publicado: (2019)

The Cardiovascular Effects of Cocoa Polyphenols—An Overview
por: Aprotosoaie, Ana Clara, et al.
Publicado: (2016)

Azithromycin, RECOVERY, and the power of large, simple trials
por: Berwanger, Otavio
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9mabrubljl47dea79565nd6bt4